

Attorney Docket No.: ISPH-0628
Inventors: Baker et al.
Serial No.: 10/067,125
Filing Date: February 4, 2002
Page 2

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (original): An antisense compound 8 to 30 nucleotides in length targeted to a nucleic acid molecule encoding a human tumor necrosis factor receptor-associated factor, wherein said antisense compound inhibits the expression of human tumor necrosis factor receptor-associated factor.

Claim 2 (original): The antisense compound of claim 1 which is an antisense oligonucleotide.

Claim 3 (original): The antisense oligonucleotide of claim 2 which comprises at least one modified internucleoside linkage.

Claim 4 (original): The antisense oligonucleotide of claim 3 wherein the modified internucleoside linkage is a phosphorothioate linkage.

Claim 5 (original): The antisense oligonucleotide of claim 2 which comprises at least one modified sugar moiety.

Claim 6 (original): The antisense oligonucleotide of claim 5 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

BEST AVAILABLE COPY

Attorney Docket No.: ISPH-0628
Inventors: Baker et al.
Serial No.: 10/067,125
Filing Date: February 4, 2002
Page 3

Claim 7 (original): The antisense oligonucleotide of claim 2 which comprises at least one modified nucleobase.

Claim 8 (original): The antisense oligonucleotide of claim 7 wherein the modified nucleobase is a 5-methylcytosine.

Claim 9 (original): The antisense compound of claim 1 which is a chimeric oligonucleotide.

Claim 10 (original): The antisense compound of claim 1 wherein the human TRAF is TRAF-2 or TRAF-6.

Claim 11 (original): A pharmaceutical composition comprising the antisense compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

Claim 12 (original): The pharmaceutical composition of claim 11 comprising a colloidal dispersion system.

Claim 13 (original): The pharmaceutical composition of claim 11 wherein the antisense compound is an antisense oligonucleotide.

Claim 14 (original): A method of inhibiting the expression of tumor necrosis factor receptor-associated factor in human cells or tissues comprising contacting said cells or tissues with the antisense compound of claim 1 so that expression of tumor necrosis factor receptor-associated factor is inhibited.

Attorney Docket No.: ISPH-0628
Inventors: Baker et al.
Serial No.: 10/067,125
Filing Date: February 4, 2002
Page 4

Claim 15 (original): A method of reducing jun kinase activation in cells or tissues by tumor necrosis factor- α comprising contacting said cells or tissues with an antisense compound targeted to TRAF-2.

Claim 16 (original): A method of reducing jun kinase activation in cells or tissues comprising contacting said cells or tissues with an antisense compound targeted to TRAF-6.

Claim 17 (original): A method of reducing E-selectin expression in cells or tissues comprising contacting said cells or tissues with an antisense compound targeted to TRAF-2 or TRAF-6.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.